Quarterly Activities & Cashflow Report
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
22 January 2024
Quarterly Activities & Appendix 4C December 2023
●
●
●
●
●
●
Biome reports record $3.3m sales revenue and $3.07m cash receipts in Q2 FY24
Biome records first ever quarter of positive operating cash flow of $81k
Underlying cash flow improved by $500k compared to the previous quarter
Record cash receipts in Q2 FY24, up 45% to $3.07m, accounts receivable increased
from $2.08m to $2.28m
Landmark agreement signed in Q2 FY24 to develop company owned IP
Biome reaffirms it is sufficiently funded to execute its FY24 strategy
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to provide its Appendix 4C and Activity Report for the quarter ended
31 December 2023.
Biome reports record sales revenue of $3.3m for the quarter while maintaining a gross
margin of 59%. This represents an 83.3% increase in quarterly sales revenue compared to
the previous corresponding period (PCP).
Quarterly Sales Revenue
Additionally, Biome achieved its first quarter of positive operating cash flow since
founding the business in July 2018. It should be noted that this result was supported by
the annual R&D rebate of $315k; however, Biome’s rapid revenue growth and contained
operating costs indicate that the company is nearing normalised positive cash flow.
As released to the market on 9 October 2023, Biome expects to achieve positive monthly
EBITDA by June 2024 and has provided FY24 sales revenue guidance of $12.5m,
representing a 74% increase vs PCP (FY23 $7.2m).
Continued high growth is expected in the second half of FY24 with business development
highlights including the company’s launch into health retail across the UK and Ireland,
new Australian pharmacies coming on board to range Activated Probiotics, and further
new product launches.
Within the quarter, Biome reached an agreement with one of its key research and
development partners to develop multiple novel probiotic strains, which Biome expects to
result in new intellectual property ownership through future patent applications.
As a key part of Biome’s next phase of growth and development, the company is working
toward growing its asset base and ownership of key raw materials. This will facilitate future
clinical research and additional long-term shareholder value.
Biome aims for these new strains to support products with both mainstream gut and
immune health targets, as well as future therapeutic development for condition-specific
biotherapeutics.
These novel probiotic strains will protect Activated Probiotics from future competition in
the marketplace, but will also allow for new, targeted applications resulting in productdevelopment opportunities globally.
Biome reaffirms it is sufficiently funded to execute its FY24 strategy.
Company Financial and Corporate Overview
Net cash inflow from operating activities for the December 2023 quarter was $81k, assisted
by R&D rebate of $315k (previous quarter net cash outflows of $734k). Without the R&D
rebate, cash outflows reduced to $234k for the quarter, an improvement of $500k over the
September quarter.
Cash at the end of the quarter was $2.024m (30 June 2023: $1.971m) with a further $200k
available for drawdown under the existing revolving debt facility with TP24.
In Q2 FY24 the Company received a record $3.07m in cash receipts from customers
(previous quarter $2.11m), representing an increase of $954k. The Company’s accounts
receivable balance has grown along with sales revenue, increasing from $2.08m at
September 30 2023 to $2.28m as at 31 December 2023, an increase of $200k.
Net business activities expenditure increased by $139k over the September quarter to
$2.99m for the December quarter. Business activities expenses consist of sales, advertising
and marketing costs of $365k (a decrease from previous quarter $439k), payments for
inventory and fulfilment increased to $1.435m (previous quarter $1.03m), other operating
costs of $37k and research and development of $100k (previous quarter $91k). The balance
of operating outflows were administration and staff costs totaling $1.329m, a slight
increase from the previous quarter’s $1.275m.
The Company notes that in the December 2023 quarter, the Company paid $136,140 to
Directors of the Company in fees, salaries and superannuation payments, as follows:
●
●
Executive Director
Non-executive Directors
$97,125
$39,015
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
BIOME AUSTRALIA LIMITED (BIO)
ABN
Quarter ended (“current quarter”)
51 627 364 014
DECEMBER 2023
Consolidated statement of cash
flows
Current
quarter $A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date
(....6...months)
$A’000
3,066
5,178
(a)
research and development
(100)
(191)
(b)
inventory & fulfilment
(1,435)
(2,464)
(c)
other operating costs
(37)
(78)
(d)
sales, advertising and
marketing
(365)
(804)
(e)
staff costs
(1,115)
(2,212)
(f)
administration and corporate
costs
(214)
(392)
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
13
27
1.5
Interest and other costs of finance paid
(37)
(57)
1.6
Income taxes & FBT paid
(10)
(12)
1.7
Government grants including EMDG
and R&D tax rebate incentives
315
352
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
81
(653)
2.
Cash flows from investing
activities
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and
equipment
(6)
(12)
(6)
(12)
(d) investments
(e) intellectual property
(f)
2.2
other non-current assets
(*leasehold improvements)
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and
equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
2.3
Cash flows from loans to other
entities
2.4
Dividends received (see note 3)
2.5
Other (**bank guarantee)
2.6
Net cash from / (used in)
investing activities
3.
Cash flows from financing
activities
3.1
Proceeds from issues of equity
securities (excluding
convertible debt securities)
3.2
Proceeds from issue of convertible
debt securities
3.3
Proceeds from issue of options
3.4
Transaction costs related to issues
of equity securities or convertible
debt securities
3.5
Proceeds from borrowings
3.6
Payments for lease liabilities
3.7
Transaction costs related to loans
and borrowings
3.8
Dividends paid
3.9
500
(24)
(48)
Other (repayments of borrowings)
(11)
(22)
3.10
Net cash from / (used in)
financing activities
(35)
430
4.
Net increase / (decrease) in
cash and cash equivalents for
the period
4.1
Cash and cash equivalents at
beginning of period
1,971
2,261
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
81
(653)
4.3
Net cash from / (used in) investing
activities (item 2.6 above)
(6)
(12)
4.4
Net cash from / (used in) financing
activities (item 3.10 above)
(35)
430
4.5
Effect of movement in exchange
rates on cash held
13
(2)
4.6
Cash and cash equivalents at end
of period
2,024
2,024
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
2,024
1,971
at the end of the quarter (as
shown in the consolidated
statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end
of quarter (should equal item 4.6
above)
2,024
1,971
6.
Payments to related parties of the entity and
their associates
6.1
Aggregate amount of payments to related parties and
their associates included in item 1
6.2
Aggregate amount of payments to related parties and
their associates included in item 2
Current quarter
$A'000
$136
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments.
The amount paid to Directors of the Company during the quarter was $136,140 in fees,
salaries and superannuation payments, as follows:
·
Executive Director
$97,125
·
Non-executive Directors
$39,015
7.
Financing facilities
Note: the term “facility’ includes all forms
of financing arrangements available to the
entity.
Add notes as necessary for an
understanding of the sources of finance
available to the entity.
7.1
Loan facilities
7.2
Total facility
amount at
quarter end
$A’000
Amount drawn
at quarter end
$A’000
1,200
1,000
Credit standby arrangements
Nil
n/a
7.3
Other (please specify)
Nil
n/a
7.4
Total financing facilities
1,200
1,000
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the
lender, interest rate, maturity date and whether it is secured or unsecured. If
any additional financing facilities have been entered into or are proposed to be
entered into after quarter end, include a note providing details of those facilities
as well.
200
Biome Australia Trading Pty Ltd (“Biome Trading”) a wholly owned subsidiary of The
Company has entered into a $1.2 million secured debt facility (“Facility”) with
Tradeplus24 (TP24) for working capital purposes to fund future growth.
The current interest rate of the Facility is 10.6872% per annum, with a portion tied to the
30-day bank Bill Swap Rate (“BBSW”) bid rate as at midday on the first working day of
each month plus a fixed margin of 6.8%. The Facility has a facility fee of 1.8% per annum.
The Facility is repayable by 31 July 2024 and is secured by a General Security
Agreement over the whole of Biome Trading’s assets, a first ranking priority charge
over the whole of Biome Trading’s receivables (debtor) book and a Deed of
Guarantee and Indemnity from the Company, supported by a General Security
Agreement over the whole of the assets of the Company as well as a Deed of
Subordination over intercompany loans. It is the company’s intention to seek a renewal
of this facility before the end of FY24 if required.
8.
Estimated cash available for future operating
activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
8.2
Cash and cash equivalents at quarter end (item 4.6)
8.3
Unused finance facilities available at quarter end (item
7.5)
200
8.4
Total available funding (item 8.2 + item 8.3)
2,305
8.5
Estimated quarters of funding available (item 8.4
divided by item 8.1)
81
2,024
N/A
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as
“N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item
8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following
questions:
8.6.1
Does the entity expect that it will continue to have the current
level of net operating cash flows for the time being and, if not,
why not?
Answer:
n/a
8.6.2
Has the entity taken any steps, or does it propose to take any
steps, to raise further cash to fund its operations and, if so, what
are those steps and how likely does it believe that they will be
successful?
Answer:
n/a
8.6.3
Does the entity expect to be able to continue its operations and
to meet its business objectives and, if so, on what basis?
Answer:
n/a
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above
must be answered.
Compliance statement
Date:
1
This statement has been prepared in accordance with accounting standards
and policies which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
22 JAN 2024
Authorised by: By the Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a
basis for informing the market about the entity’s activities for the past quarter, how
they have been financed and the effect this has had on its cash position. An entity that
wishes to disclose additional information over and above the minimum required under
the Listing Rules is encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with
Australian Accounting Standards, the definitions in, and provisions of, AASB 107:
Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to
Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating
activities or cash flows from investing activities, depending on the accounting policy of
the entity.
4.
If this report has been authorised for release to the market by your board of
directors, you can insert here: “By the board”. If it has been authorised for release to the
market by a committee of your board of directors, you can insert here: “By the [name of
board committee – eg Audit and Risk Committee]”. If it has been authorised for release
to the market by a disclosure committee, you can insert here: “By the Disclosure
Committee”.
5.
If this report has been authorised for release to the market by your board of
directors and you wish to hold yourself out as complying with recommendation 4.2 of
the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and
CFO that, in their opinion, the financial records of the entity have been properly
maintained, that this report complies with the appropriate accounting standards and
gives a true and fair view of the cash flows of the entity, and that their opinion has been
formed on the basis of a sound system of risk management and internal control which
is operating effectively.
Upcoming Activities
1
Audited half year results
27 February 2024
2
Biome Daily Kids clinical trial preliminary
Q3 FY24
results
3
Biome Cholesterol Probiotic Launch
Q4 FY24
4
Biome Osteo clinical trial preliminary results
Q4 FY24
–ENDS–
Approved for release by the Biome Australia board of directors.
Investor Hub
Biome has launched a new interactive investor hub. To view a video presentation of this
announcement, ask questions or sign up for future company updates, please visit the
investor hub via this link (https://investorhub.biomeaustralia.com/).
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-based
live biotherapeutics (probiotics) and complementary medicines, many of which are
supported by clinical research. Biome aims to improve health outcomes and quality of life,
and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development, Biome
produced several unique live biotherapeutic (probiotic) products with innovative delivery
technologies that improve their stability and efficacy to create its flagship range of
complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials,
Activated Probiotics help prevent and support the management of various health concerns,
including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS.
Through practitioner-only distribution, Biome is committed to educating health
professionals on the newfound systemic health effects of the gut microbiota, helping them
to provide innovative, evidence-based natural medicines for the management of some of
humanity's most prevalent and chronic health concerns.
Biome also develops, licenses and distributes a scientifically formulated, organic
nutraceutical range, Activated Nutrients®.
For more information visit: www.biomeaustralia.com
Investor Relations
Jo Power
corporate@biomeaustralia.com
(03) 9017 5800
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon as
an indication or guarantee of future performance. Actual results, performance or achievements may
differ materially from those expressed or implied in such Forward Looking Statements and any
projections and assumptions on which these Forward Looking Statements are based. Such
statements may assume the success of Biome's business strategies. You are cautioned not to place
undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of this
release. Any Forward Looking Statements containing forward looking financial information provided
in this release is for illustrative purposes only and is not represented as being indicative of Biome's
views on its future financial condition and/or performance. The historic financial information for the
September 2021 financial quarter and revenue figures for October and November 2021 have not been
audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future
performance.
Nothing in this release is a promise or representation as to the future. No representation or warranty,
express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
Forward Looking Statements contained in this release. Except as required by law or regulation
(including the ASX Listing Rules), Biome does not undertake to provide any additional or updated
information whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness, currency,
accuracy, reliability or completeness of information in this release or the accuracy, likelihood of
achievement or reasonableness of any Forward Looking Statements (or any event or results expressed
or implied in any Forward Looking Statements) contained in, implied by, the information in this
release or any part of it, or that this release contains all material information about Biome or which a
prospective investor or purchaser may require in evaluating a possible investment in Biome or
acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover